
Chiara Agrati

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4910062/publications.pdf Version: 2024-02-01



#	ARTICLE	IF	CITATIONS
1	Humoral and T-Cell Immune Response After 3 Doses of Messenger RNA Severe Acute Respiratory Syndrome Coronavirus 2 Vaccines in Fragile Patients: The Italian VAX4FRAIL Study. Clinical Infectious Diseases, 2023, 76, e426-e438.	2.9	23
2	Association of Sofosbuvir and Daclatasvir Plasma Trough Concentrations with Patient-, Treatment-, and Disease-Related Factors Among HIV/HCV-Coinfected Persons. European Journal of Drug Metabolism and Pharmacokinetics, 2022, 47, 135-142.	0.6	0
3	GRAd-COV2, a gorilla adenovirus-based candidate vaccine against COVID-19, is safe and immunogenic in younger and older adults. Science Translational Medicine, 2022, 14, eabj1996.	5.8	18
4	Coordinated cellular and humoral immune responses after twoâ€dose SARSâ€CoV2 mRNA vaccination in liver transplant recipients. Liver International, 2022, 42, 180-186.	1.9	36
5	In Acute Dengue Infection, High TIM-3 Expression May Contribute to the Impairment of IFNÎ ³ Production by Circulating Vδ2 T Cells. Viruses, 2022, 14, 130.	1.5	6
6	The interplay between SARS-CoV-2 infected airway epithelium and immune cells modulates regulatory/inflammatory signals. IScience, 2022, 25, 103854.	1.9	3
7	Virological and Immunological Outcomes of an Intensified Four-Drug versus a Standard Three-Drug Antiretroviral Regimen, Both Integrase Strand Transfer Inhibitor-Based, in Primary HIV Infection. Pharmaceuticals, 2022, 15, 403.	1.7	2
8	Characteristics and Outcomes of COVID-19-Related Hospitalization among PLWH. Journal of Clinical Medicine, 2022, 11, 1546.	1.0	8
9	Humoral and Cellular Immune Response Elicited by mRNA Vaccination Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in People Living With Human Immunodeficiency Virus Receiving Antiretroviral Therapy Based on Current CD4 T-Lymphocyte Count. Clinical Infectious Diseases, 2022, 75, e552-e563.	2.9	79
10	Use of Pembrolizumab for Treatment of Progressive Multifocal Leukoencephalopathy in People Living with HIV. Viruses, 2022, 14, 970.	1.5	3
11	^{ĵ3} δT Cells in Emerging Viral Infection: An Overview. Viruses, 2022, 14, 1166.	1.5	3
12	Interpatient variability in the pharmacokinetics of remdesivir and its main metabolite GS-441524 in treated COVID-19 subjects. Journal of Antimicrobial Chemotherapy, 2022, 77, 2683-2687.	1.3	3
13	COVIDâ€19 in people living with HIV: Clinical implications of dynamics of the immune response to SARSâ€CoVâ€2. Journal of Medical Virology, 2021, 93, 1796-1804.	2.5	38
14	Plasma concentrations of remdesivir metabolite in a critical COVID-19 patient needing continuous venovenous haemodialysis. European Journal of Clinical Pharmacology, 2021, 77, 1583-1585.	0.8	3
15	Prophylactic heparin and risk of orotracheal intubation or death in patients with mild or moderate COVID-19 pneumonia. Scientific Reports, 2021, 11, 11334.	1.6	2
16	Coordinate Induction of Humoral and Spike Specific T-Cell Response in a Cohort of Italian Health Care Workers Receiving BNT162b2 mRNA Vaccine. Microorganisms, 2021, 9, 1315.	1.6	54
17	Fibrogenic signals persist in DAA-treated HCV patients after sustained virological response. Journal of Hepatology, 2021, 75, 1301-1311.	1.8	15
18	Myocarditis-associated necrotizing coronary vasculitis: incidence, cause, and outcome. European Heart Journal, 2021, 42, 1609-1617.	1.0	8

#	Article	IF	CITATIONS
19	Vitamin D as Modulator of Drug Concentrations: A Study on Two Italian Cohorts of People Living with HIV Administered with Efavirenz. Nutrients, 2021, 13, 3571.	1.7	2
20	Strong immunogenicity of heterologous prime-boost immunizations with the experimental vaccine GRAd-COV2 and BNT162b2 or ChAdOx1-nCOV19. Npj Vaccines, 2021, 6, 131.	2.9	18
21	Impact of ART on dynamics of growth factors and cytokines in primary HIV infection. Cytokine, 2020, 125, 154839.	1.4	12
22	Per2 Upregulation in Circulating Hematopoietic Progenitor Cells During Chronic HIV Infection. Frontiers in Cellular and Infection Microbiology, 2020, 10, 362.	1.8	6
23	Early expansion of myeloid-derived suppressor cells inhibits SARS-CoV-2 specific T-cell response and may predict fatal COVID-19 outcome. Cell Death and Disease, 2020, 11, 921.	2.7	96
24	An Inflammatory Profile Correlates With Decreased Frequency of Cytotoxic Cells in Coronavirus Disease 2019. Clinical Infectious Diseases, 2020, 71, 2272-2275.	2.9	91
25	Pharmacokinetics of remdesivir and GS-441524 in two critically ill patients who recovered from COVID-19. Journal of Antimicrobial Chemotherapy, 2020, 75, 2977-2980.	1.3	90
26	Immunological and inflammatory profiles in mild and severe cases of COVID-19. Nature Communications, 2020, 11, 3410.	5.8	328
27	Persistent gamma delta Tâ€cell dysfunction in HCV/HIV coâ€infection despite directâ€acting antiviral therapyâ€induced cure. Journal of Viral Hepatitis, 2020, 27, 754-756.	1.0	2
28	Multicentre Harmonisation of a Six-Colour Flow Cytometry Panel for NaÃ ⁻ ve/Memory T Cell Immunomonitoring. Journal of Immunology Research, 2020, 2020, 1-15.	0.9	8
29	The importance of advanced cytometry in defining new immune cell types and functions relevant for the immunopathogenesis of HIV infection. Aids, 2020, 34, 2169-2185.	1.0	2
30	Myeloid Derived Suppressor Cells Expansion Persists After Early ART and May Affect CD4 T Cell Recovery. Frontiers in Immunology, 2019, 10, 1886.	2.2	15
31	Vδ2 T-Cells Kill ZIKV-Infected Cells by NKG2D-Mediated Cytotoxicity. Microorganisms, 2019, 7, 350.	1.6	9
32	In Human Immunodeficiency Virus primary infection, early combined antiretroviral therapy reduced <i>Î3δ</i> T ell activation but failed to restore their polyfunctionality. Immunology, 2019, 157, 322-330.	2.0	6
33	Unawareness of HCV serostatus among persons newly diagnosed with HIV. Journal of Infection and Public Health, 2019, 12, 733-737.	1.9	2
34	GB virus type C crossâ€reactivity in clinical samples with a low hepatitis C virus antibody positive response. Apmis, 2019, 127, 109-111.	0.9	0
35	NaÃ ⁻ ve/Effector CD4 T cell ratio as a useful predictive marker of immune reconstitution in late presenter HIV patients: A multicenter study. PLoS ONE, 2019, 14, e0225415.	1.1	15
36	Unexpected human cases of cutaneous anthrax in Latium region, Italy, August 2017: integrated human–animal investigation of epidemiological, clinical, microbiological and ecological factors. Eurosurveillance, 2019, 24, .	3.9	5

#	Article	IF	CITATIONS
37	IL-18 and Stem Cell Factor affect hematopoietic progenitor cells in HIV-infected patients treated during primary HIV infection. Cytokine, 2018, 103, 34-37.	1.4	8
38	Plasma trough concentrations of antiretrovirals in HIV-infected persons treated with direct-acting antiviral agents for hepatitis C in the real world. Journal of Antimicrobial Chemotherapy, 2018, 73, 160-164.	1.3	2
39	Hepatitis C virus directâ€acting antivirals therapy impacts on extracellular vesicles microRNAs content and on their immunomodulating properties. Liver International, 2018, 38, 1741-1750.	1.9	35
40	UPLC–MS/MS method for the simultaneous quantification of sofosbuvir, sofosbuvir metabolite (GS-331007) and daclatasvir in plasma of HIV/HCV co-infected patients. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2018, 1073, 183-190.	1.2	34
41	A new procedure to analyze polymorphonuclear myeloid derived suppressor cells in cryopreserved samples cells by flow cytometry. PLoS ONE, 2018, 13, e0202920.	1.1	7
42	ZIKV Infection Induces an Inflammatory Response but Fails to Activate Types I, II, and III IFN Response in Human PBMC. Mediators of Inflammation, 2018, 2018, 1-6.	1.4	28
43	Myeloid-Derived Suppressor Cells Specifically Suppress IFN-Î ³ Production and Antitumor Cytotoxic Activity of Vδ2 T Cells. Frontiers in Immunology, 2018, 9, 1271.	2.2	35
44	Bone Marrow CD34 ⁺ Progenitor Cells from HIV-Infected Patients Show an Impaired T Cell Differentiation Potential Related to Proinflammatory Cytokines. AIDS Research and Human Retroviruses, 2017, 33, 590-596.	0.5	17
45	In HIV/HCV co-infected patients T regulatory and myeloid-derived suppressor cells persist after successful treatment with directly acting antivirals. Journal of Hepatology, 2017, 67, 422-424.	1.8	20
46	HIV-Specific CD8 T Cells Producing CCL-4 Are Associated With Worse Immune Reconstitution During Chronic Infection. Journal of Acquired Immune Deficiency Syndromes (1999), 2017, 75, 338-344.	0.9	12
47	Dendritic cells activation is associated with sustained virological response to telaprevir treatment of HCV-infected patients. Clinical Immunology, 2017, 183, 82-90.	1.4	Ο
48	Human Zika infection induces a reduction of IFN-Î ³ producing CD4 T-cells and a parallel expansion of effector Vδ2 T-cells. Scientific Reports, 2017, 7, 6313.	1.6	35
49	Granulocytic Myeloid–Derived Suppressor Cells Increased in Early Phases of Primary HIV Infection Depending on TRAIL Plasma Level. Journal of Acquired Immune Deficiency Syndromes (1999), 2017, 74, 575-582.	0.9	25
50	Measles Cases during Ebola Outbreak, West Africa, 2013–2106. Emerging Infectious Diseases, 2017, 23, 1035-1037.	2.0	21
51	Different features of Vδ2 T and NK cells in fatal and non-fatal human Ebola infections. PLoS Neglected Tropical Diseases, 2017, 11, e0005645.	1.3	46
52	Unique human immune signature of Ebola virus disease in Guinea. Nature, 2016, 533, 100-104.	13.7	170
53	The Different Roles of Interleukin 7 and Interleukin 18 in Affecting Lymphoid Hematopoietic Progenitor Cells and CD4 Homeostasis in Naive Primary and Chronic HIV-Infected Patients. Clinical Infectious Diseases, 2016, 63, 1683-1684.	2.9	3
54	Antiviral activity of human Vδ2 T-cells against WNV includes both cytolytic and non-cytolytic mechanisms. New Microbiologica, 2016, 39, 139-42.	0.1	5

#	Article	IF	CITATIONS
55	In HIV-positive patients, myeloid-derived suppressor cells induce T-cell anergy by suppressing CD3ζ expression through ELF-1 inhibition. Aids, 2015, 29, 2397-2407.	1.0	48
56	Primary and Chronic HIV Infection Differently Modulates Mucosal Vδ1 and Vδ2 T-Cells Differentiation Profile and Effector Functions. PLoS ONE, 2015, 10, e0129771.	1.1	17
57	Vγ9Vδ2 T-Cell Polyfunctionality Is Differently Modulated in HAART-Treated HIV Patients according to CD4 T-Cell Count. PLoS ONE, 2015, 10, e0132291.	1.1	10
58	Diagnostic performances of clinical laboratory tests using Triton X-100 to reduce the biohazard associated with routine testing of Ebola virus-infected patients. Clinical Chemistry and Laboratory Medicine, 2015, 53, 1967-73.	1.4	14
59	Early ART in primary HIV infection may also preserve lymphopoiesis capability in circulating haematopoietic progenitor cells: a case report. Journal of Antimicrobial Chemotherapy, 2015, 70, 1598-1600.	1.3	6
60	Molecular characterization of hepatitis A outbreak in the province of Rome, Lazio region, Italy, January–July 2013. Microbes and Infection, 2014, 16, 362-366.	1.0	5
61	Cellular and Humoral Cross-Immunity against Two H3N2v Influenza Strains in Presumably Unexposed Healthy and HIV-Infected Subjects. PLoS ONE, 2014, 9, e105651.	1.1	5
62	HIV Infection of Monocytes-Derived Dendritic Cells Inhibits Vγ9Vδ2 T Cells Functions. PLoS ONE, 2014, 9, e111095.	1.1	12
63	Brain localization of Kaposi's sarcoma in a patient treated by combination antiretroviral therapy. BMC Infectious Diseases, 2013, 13, 600.	1.3	11
64	Chronic HIV-Infected Patients Show an Impaired Dendritic Cells Differentiation of Bone Marrow CD34+ Cells. Journal of Acquired Immune Deficiency Syndromes (1999), 2013, 64, 342-344.	0.9	7
65	<i>In Vivo</i> Interferon-Alpha/Ribavirin Treatment Modulates Vγ9Vδ2 T-Cell Function During Chronic HCV Infection. Journal of Interferon and Cytokine Research, 2013, 33, 136-141.	0.5	8
66	In HIV-infected patients, some differential alterations of CD4 and CD8 T cell homeostasis may not be restored by >=7 years of highly active antiretroviral therapy, in spite of good CD4 T cell repopulation. Journal of Antimicrobial Chemotherapy, 2012, 67, 1802-1804.	1.3	4
67	Cellular and Humoral Immune Responses to Pandemic Influenza Vaccine in Healthy and in Highly Active Antiretroviral Therapy-Treated HIV Patients. AIDS Research and Human Retroviruses, 2012, 28, 1606-1616.	0.5	12
68	Interferon-α Improves Phosphoantigen-Induced Vγ9Vδ2 T-Cells Interferon-γ Production during Chronic HCV Infection. PLoS ONE, 2012, 7, e37014.	1.1	23
69	The basal activation state of DC subsets correlates with anti-HCV treatment outcome in HCV/HIV co-infected patients. Clinical Immunology, 2011, 138, 178-186.	1.4	6
70	Multicompartment vectors as novel drug delivery systems: selective activation of Tγδlymphocytes after zoledronic acid delivery. Nanomedicine: Nanotechnology, Biology, and Medicine, 2011, 7, 153-161.	1.7	28
71	Innate gamma/delta T-cells during HIV infection: Terra relatively Incognita in novel vaccination strategies?. AIDS Reviews, 2011, 13, 3-12.	0.5	42
72	Association of Profoundly Impaired Immune Competence in H1N1vâ€Infected Patients with a Severe or Fatal Clinical Course. Journal of Infectious Diseases, 2010, 202, 681-689.	1.9	50

#	Article	IF	CITATIONS
73	Activated Vγ9VÎ′2 T Cells Trigger Granulocyte Functions via MCP-2 Release. Journal of Immunology, 2009, 182, 522-529.	0.4	35
74	Cutting Edge: TGF-β1 and IL-15 Induce FOXP3+ γδRegulatory T Cells in the Presence of Antigen Stimulation. Journal of Immunology, 2009, 183, 3574-3577.	0.4	147
75	CD3ζ Downâ€Modulation May Explain Vγ9VÎ′2 T Lymphocyte Anergy in HIVâ€Infected Patients. Journal of Infectious Diseases, 2009, 199, 432-436.	1.9	8
76	In vivo effects of zoledronic acid on peripheral Î ³ δT lymphocytes in early breast cancer patients. Cancer Immunology, Immunotherapy, 2009, 58, 31-38.	2.0	96
77	Zoledronic acid and interleukin-2 treatment improves immunocompetence in HIV-infected persons by activating Vγ9Vδ2 T cells. Aids, 2009, 23, 555-565.	1.0	55
78	Influenza Pandemics, Immune Crossâ€Reactivity, and Pandemic Control Strategies. Journal of Infectious Diseases, 2008, 198, 294-295.	1.9	5
79	Administration of PLP139–151 Primes T Cells Distinct from Those Spontaneously Responsive In Vitro to This Antigen. Journal of Immunology, 2008, 180, 6611-6622.	0.4	19
80	Do human Î ³ δT cells respond to M tuberculosis protein antigens?. Blood, 2008, 112, 4776-4777.	0.6	4
81	Cross-subtype Immunity against Avian Influenza in Persons Recently Vaccinated for Influenza. Emerging Infectious Diseases, 2008, 14, 121-128.	2.0	81
82	Accumulation of dysfunctional effector CD8+T cells in the liver of patients with chronic HCV infection. Journal of Hepatology, 2006, 44, 475-483.	1.8	20
83	Activation of Vγ9Vδ2 T cells by non-peptidic antigens induces the inhibition of subgenomic HCV replication. International Immunology, 2006, 18, 11-18.	1.8	56
84	Interferonâ€Î³â€"Mediated Antiviral Immunity against Orthopoxvirus Infection Is Provided by γδT Cells. Journal of Infectious Diseases, 2006, 193, 1606-1607.	1.9	13
85	Anti–Severe Acute Respiratory Syndrome Coronavirus Immune Responses: The Role Played by Vγ9Vδ2 T Cells. Journal of Infectious Diseases, 2006, 193, 1244-1249.	1.9	78
86	Vγ9Vδ2 T cell-mediated non-cytolytic antiviral mechanisms and their potential for cell-based therapy. Immunology Letters, 2005, 100, 14-20.	1.1	35
87	Coordinate induction of IFN-α and -γ by SARS-CoV also in the absence of virus replication. Virology, 2005, 341, 163-169.	1.1	40
88	Antiviral reactivities of $\hat{I}^3\hat{I}^{\prime}$ T cells. Microbes and Infection, 2005, 7, 518-528.	1.0	84
89	Non-Pathogenic Mycobacterium smegmatis Induces the Differentiation of Human Monocytes Directly into Fully Mature Dendritic Cells. Journal of Clinical Immunology, 2005, 25, 365-375.	2.0	15
90	Influence of GB Virus Type C and HIV Coinfection on ÂÂ T cells. Clinical Infectious Diseases, 2005, 40, 326-328.	2.9	4

#	Article	IF	CITATIONS
91	Steatosis and intrahepatic lymphocyte recruitment in hepatitis C virus transgenic mice. Journal of General Virology, 2004, 85, 1509-1520.	1.3	41
92	Murine hepatocyte cell lines promote expansion and differentiation of NK cells from stem cell precursors. Hepatology, 2004, 39, 1508-1516.	3.6	15
93	Highly Active Antiretroviral Therapy Restores CD4+ V?? T-Cell Repertoire in Patients With Primary Acute HIV Infection But Not in Treatment-Naive HIV+ Patients With Severe Chronic Infection. Journal of Acquired Immune Deficiency Syndromes (1999), 2004, 35, 213-222.	0.9	25
94	P-Glycoprotein Expression by Peripheral Blood Mononuclear Cells from Human Immunodeficiency Virus-Infected Patients Is Independent from Response to Highly Active Antiretroviral Therapy. Vaccine Journal, 2003, 10, 191-192.	3.2	5
95	Expansion of pre-terminally differentiated CD8 T cells in chronic HIV-positive patients presenting a rapid viral rebound during structured treatment interruption. Aids, 2002, 16, 2431-2438.	1.0	29
96	Acute Human Immunodeficiency Virus Replication Causes a Rapid and Persistent Impairment of Vγ9Vδ2 T Cells in Chronically Infected Patients Undergoing Structured Treatment Interruption. Journal of Infectious Diseases, 2002, 186, 847-850.	1.9	46
97	Lack of CD27â^CD45RAâ^Vγ9VÎ′2+ T Cell Effectors in Immunocompromised Hosts and During Active Pulmonary Tuberculosis. Journal of Immunology, 2002, 168, 1484-1489.	0.4	104
98	Lymphocyte distribution and intrahepatic compartmentalization during HCV infection: a main role for MHC-unrestricted T cells. Archivum Immunologiae Et Therapiae Experimentalis, 2002, 50, 307-16.	1.0	7
99	Vδ1T Lymphocytes Expressing a Th1 Phenotype Are the Major γδT Cell Subset Infiltrating the Liver of HCV-infected Persons. Molecular Medicine, 2001, 7, 11-19.	1.9	50
100	Î ³ ÎT Cell Activation by Chronic HIV Infection May Contribute to Intrahepatic VδI Compartmentalization and Hepatitis C Virus Disease Progression Independent of Highly Active Antiretroviral Therapy. AIDS Research and Human Retroviruses, 2001, 17, 1357-1363.	0.5	31
101	Modulation of cholinergic marker expression by nerve growth factor in dorsal root ganglia. Journal of Neuroscience Research, 2000, 62, 591-599.	1.3	8
102	Expression of muscarinic m2 receptor mRNA in dorsal root ganglia of neonatal rat. Brain Research, 1999, 824, 63-70.	1.1	25